Inventor · disambiguated record
Hq Han
Also filed as: HAN HQ
11 granted patents·9 pending applications·197 citations·filing 2003–2024
91Inventor score
Top patents by PatentIndex Score
20 records- 0196US8410043B2Stabilized activin IIB receptor polypeptides and uses thereofSUN JEONGHOON·Filed 2009·Granted Apr 2, 2013·54 cites·15 claims
- 0295US7803923B2Polynucleotides encoding myostatin binding agentsAMGEN INC·Filed 2009·Granted Sep 28, 2010·24 cites·15 claims
- 0395US7511012B2Myostatin binding agentsAMGEN INC·Filed 2003·Granted Mar 31, 2009·47 cites·22 claims
- 0494US8067562B2Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1HAN HQ·Filed 2006·Granted Nov 29, 2011·30 cites·11 claims
- 0593US7928075B2Binding agents which inhibit myostatinAMGEN INC·Filed 2009·Granted Apr 19, 2011·14 cites·9 claims
- 0691US8071538B2Method of increasing muscle mass by administering a myostatin binding agentHAN HQ·Filed 2010·Granted Dec 6, 2011·14 cites·4 claims
- 0790US8614292B2Isolated protein comprising an activin type IIB5 receptor polypeptide and uses thereofHAN HQ·Filed 2011·Granted Dec 24, 2013·13 cites·16 claims
- 0880US2024262883A1Novel hybrid actriib ligand trap proteins for treating muscle wasting diseasesALIVEGEN INC·Filed 2024·Application pending·0 cites
- 0978US10913782B2Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseasesBIOGEN MA INC·Filed 2016·Granted Feb 9, 2021·1 cites·28 claims
- 1078US2025109183A1Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteinsALIVEGEN INC·Filed 2024·Application pending·0 cites
- 1175US11932677B2Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseasesALIVEGEN INC·Filed 2022·Granted Mar 19, 2024·0 cites·4 claims
- 1274US11292826B2Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseasesBIOGEN MA INC·Filed 2020·Granted Apr 5, 2022·0 cites·16 claims
- 1373US12187783B2Methods for treating muscle wasting and bone disease using novel hybrid ActRIIB ligand trap proteinsALIVEGEN INC·Filed 2021·Granted Jan 7, 2025·0 cites·8 claims
- 1459US2019330307A1Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteinsBIOGEN MA INC·Filed 2017·Application pending·0 cites
- 1559US2012083442A1Myostatin binding agentsHAN HQ·Filed 2011·Application pending·0 cites
- 1657US2023391863A1Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereofHAN HQ·Filed 2021·Application pending·0 cites
- 1757US2024343788A1Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereofHAN HQ·Filed 2021·Application pending·0 cites
- 1857US2023391880A1Bifunctional antagonists of activin/tgf-beta and rankl and uses thereofHAN HQ·Filed 2021·Application pending·0 cites
- 1956US2023391892A1Bifunctional antagonists of tumor necrosis factor alpha and transforming growth factor beta and uses thereofHAN HQ·Filed 2021·Application pending·0 cites
- 2055US2007149458A1Uses of myostatin antagonistsAMGEN INC·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hq Han files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →